SCHEMBL5378299

SCHEMBL5378299

O=C(CCC(=O)N1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1ccc2ccccc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLD1 Q13393 4/20 0.62
PLD2 O14939 3/20 0.62
HSD11B1 P28845 11/20 0.57
CHRM2 P08172 2/20 0.55
CHRM1 P11229 2/20 0.55
CHRM3 P20309 2/20 0.55
MLNR O43193 1/20 0.55
LMNA P02545 1/20 0.55
PGR P06401 1/20 0.55
ADRB2 P07550 1/20 0.55
ADRB1 P08588 1/20 0.55
HTR1A P08908 1/20 0.55
ADRA2A P08913 1/20 0.55
CYP2D6 P10635 1/20 0.55
DRD2 P14416 1/20 0.55
GABRA1 P14867 1/20 0.55
ADRA2B P18089 1/20 0.55
ADRA2C P18825 1/20 0.55
DRD1 P21728 1/20 0.55
DRD4 P21917 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11796427 0.86 CHRM1 (0.74) PLD1PLD2HSD11B1CHRM2CHRM1
SCHEMBL5372045 0.85 HSD11B1 (0.57) HSD11B1CHRM2CHRM1CHRM3MLNR
SCHEMBL11033245 0.85 PLD2 (0.71) PLD1PLD2HSD11B1CHRM2CHRM1
SCHEMBL31285930 0.83 CYP3A4 (0.61) PLD1PLD2HSD11B1CHRM2CHRM1
SCHEMBL22587788 0.83 CYP3A4 (0.61) PLD1PLD2HSD11B1CHRM2CHRM1
SCHEMBL5367571 0.83 HSD11B1 (0.52) HSD11B1CHRM2CHRM1CHRM3MLNR
SCHEMBL5367698 0.82 TNKS (0.60) PLD1PLD2HSD11B1CHRM2CHRM1
SCHEMBL5369994 0.81 HSD11B1 (0.51) PLD1PLD2HSD11B1CHRM2CHRM1
SCHEMBL13907714 0.78 HSD11B1 (0.57) HSD11B1CHRM2CHRM1CHRM3MLNR
SCHEMBL22587867 0.78 CHRM1 (0.69) HSD11B1CHRM2CHRM1CHRM3CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070208036-A1 Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-09-06 US disclosed
US-7230001-B1 Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208036-A1 Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them ARRB1, NPY1R, ADRB3 PLD1 2412/4885PLD2 2346/4885HSD11B1 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.